Last reviewed · How we verify
Placebo-Metformin
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo-Metformin |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing peripheral glucose uptake and utilization. It may also improve insulin secretion and reduce intestinal glucose absorption. The drug does not stimulate insulin release, making it weight-neutral and suitable for use across a range of patient populations.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare)
Key clinical trials
- Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (PHASE3)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-Metformin CI brief — competitive landscape report
- Placebo-Metformin updates RSS · CI watch RSS
- Steno Diabetes Center Copenhagen portfolio CI